BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//BioCatalystFeed//bcf//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:BioCatalystFeed MLTX catalysts
X-WR-CALDESC:Scheduling/reference data from public records\; dates can move
 . Not investment\, legal or medical advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:98a73efb0a1eb55126a7@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20270104
DTEND;VALUE=DATE:20270105
SUMMARY:MLTX P3 readout (est.): IZAR-2
DESCRIPTION:Evaluation of Sonelokimab in Patients With Active Psoriatic Art
 hritis and Anti-TNFα Inadequate Response\nNCT06641089 | PHASE3 | ACTIVE_N
 OT_RECRUITING | sponsor: MoonLake Immunotherapeutics AG\nPrimary completio
 n date (ESTIMATED)\; top-line results usually follow later.\nTicker MLTX (
 confidence 0.9)\nSource: https://clinicaltrials.gov/study/NCT06641089\nSch
 eduling/reference data from public records\; dates can move. Not investmen
 t\, legal or medical advice.
TRANSP:TRANSPARENT
URL:https://clinicaltrials.gov/study/NCT06641089
CATEGORIES:readout,ESTIMATED
END:VEVENT
BEGIN:VEVENT
UID:7419082befd4a75f488a@biocat.ai
DTSTAMP:20261118T181353Z
DTSTART;VALUE=DATE:20261101
DTEND;VALUE=DATE:20261102
SUMMARY:MLTX PDUFA (company-disclosed): PDUFA November 2026 - MoonLake Immu
 notherapeutics
DESCRIPTION:PDUFA November 2026 - MoonLake Immunotherapeutics\nConfidence: 
 company-disclosed\nDate precision: month (shown on the first day)\nTicker 
 MLTX (confidence 1.0)\nSource: https://www.sec.gov/Archives/edgar/data/182
 1586/000121390026070362/ea029539901ex99-1.htm\nScheduling/reference data f
 rom public records\; dates can move. Not investment\, legal or medical adv
 ice.
TRANSP:TRANSPARENT
URL:https://www.sec.gov/Archives/edgar/data/1821586/000121390026070362/ea02
 9539901ex99-1.htm
CATEGORIES:pdufa,company-disclosed
END:VEVENT
END:VCALENDAR
